The intrinsic innate immunity of hepatocytes is essential for the control of hepatitis viruses and influences the outcome of antiviral therapy. is the most abundant microRNA in hepatocytes and is a central player in liver biology and disease.
INTRODUCTION
Viral infection is a leading cause of liver diseases. The first line of immune defence against hepatitis viruses is the cell-intrinsic innate immunity within hepatocytes, which recognizes viruses as nonself and induces local antiviral defences in the infected cell and liver tissue that recruit and modulate the actions of the immune cells of the adaptive immune response 1 . It is now well-recognized that innate immunity not only plays a critical role in the initial containment of viraemia during acute infections but also continues to contribute throughout the course of a persistent viral infection 2 . Therefore, a greater understanding of the mechanism and regulation of innate immunity can pave the way for highly effective therapies.
Among the five hepatitis viruses, hepatitis C virus (HCV) affects more than 170 million people worldwide; most patients (80-85%) who become acutely infected cannot clear this virus, and the infection becomes chronic 3 . A substantial amount of data have shown that both spontaneous and therapy-induced HCV clearance are significantly associated with genetic variations in IFNL3 and IFNL4, two interferon (IFN) genes of the type III IFN family (also known as IFN-λs) (summarized in reference 4) 4 . Very recently, the favourable IFNL3 genotype has been suggested to increase the expression of IFNλ3 (also known as IL-28B) [4] [5] [6] .
Since type III IFNs have a primary antiviral role 7, 8 and constitute the dominant IFN subclass produced by hepatocytes in response to HCV infection [9] [10] [11] , these observations suggest that reinforcing innate IFN-signalling in infected cells may be an effective approach towards a cure for HCV.
MicroRNAs (miRNAs) are a large family of small non-coding RNAs that regulate various developmental and physiological processes 12 . While most miRNAs are ubiquitously expressed, a set of miRNAs are expressed with a higher degree of tissue specificity 13 and are linked to specific functions in individual tissues or cell types 14 . MicroRNA-122 (miR-122) is a liver-specific miRNA that is exclusively expressed in hepatocytes 13 . Antisense-mediated inhibition 15, 16 and knockout studies 17, 18 demonstrate a critical role for this miRNA in the maintenance of liver homeostasis and hepatocyte function. Meanwhile, miR-122 is down-regulated or lost in human hepatocellular carcinoma (HCC) [19] [20] [21] , and delivering miR-122 mimics significantly inhibited the growth of HCC xenografts in nude mice 21, 22 ,
indicating that miR-122 serves as a tumour suppressor. Currently, the restoration of miR-122 levels has been suggested as a therapeutic approach in liver fibrosis and HCC development 23 .
However, in contrast, miR-122 plays an undesirable role in the HCV life cycle 24 . miR-122 can be recruited to the 5′-end of HCV genomic RNA 24 , where it has a positive effect on viral translation, replication and stabilization [25] [26] [27] [28] [29] [30] [31] . Accordingly, antagonizing miR-122 as a novel approach for treating HCV infection has gained clinical interest 32, 33 .
Currently, although miR-122 has been recognized as a key player in liver biology and disease, whether miR-122 regulates hepatocyte innate immunity is unclear. Several important clues have implied the possible involvement of miR-122 in hepatic innate immunity. First, although miR-122 is required for the HCV life cycle, clinical observations have shown that deceased miR-122 levels in individuals with hepatitis C are associated with a poor response to interferon therapy 34, 35 , suggesting that miR-122 may promote the IFN response in infected 6 hepatocytes. Second, the innate immune response is robust in primary hepatocytes but is strongly impaired in most hepatoma cell lines (in which miR-122 is significantly down-regulated or lost) 36, 37 . Third, miR-122 has an antiviral role in HBV infection 38, 39 ; perhaps this effect is achieved partially by modulating the innate immunity. Finally, given that miR-122 is a formidable tumour suppressor and its loss results in hepatitis 17, 18 , this miRNA may take part in the regulation of hepatic immunity. Our current study was initially aimed at investigating if miR-122 regulates the hepatocyte IFN response to HCV RNA. We were surprised to find that miR-122 markedly enhanced the IFN response to HCV but was not specific to HCV. Importantly, we found that miR-122 promotes IFN expression by down-regulating STAT3 phosphorylation, which inhibits IRF1 and represses the transcriptional activation of IFNs. Therefore, our findings have identified a previously undiscovered network that links miR-122 to hepatic immunity through STAT3.
RESULTS miR-122 enhances the hepatocyte IFN response to HCV RNA
To select a stable and reliable cell model for our study, we examined the functional innate immunity of three human hepatoma-derived cell lines: HepG2, Huh7 and Huh7.5.1 40 . Since HCV RNA is the predominant stimulator of the IFN response 41 , we transfected JFH1 42 HCV genome RNA into these cell lines and then measured the induction of STAT1 phosphorylation Supplementary Fig. 1b) , which is similar to observations in primary human hepatocytes and in vivo studies [9] [10] [11] . Therefore, HepG2 may be a suitable cell model for studying innate hepatocyte immune responses.
To determine whether miR-122 is involved in hepatocyte immunity to HCV, we transfected (Fig. 1a) . Consistent with the previous findings that miR-122 promotes HCV translation, an substantial increase in the expression of HCV core and non-structural 3 (NS3)
proteins was observed in miR-122-transfected groups (Fig. 1b) . Surprisingly, miR-122 originally inhibited p-STAT1 but dramatically enhanced p-STAT1 induction after HCV RNA stimulation, with the most significant difference at 24 h post HCV transfection (Fig. 1b) . The MDA5 results were similar (Fig. 1b) . The analysis of IFN mRNA levels revealed that miR-122 strikingly increased not only IFN-λs (IL-29 increased >300-fold, IL-28 increased >100-fold) but also IFN-β (increased >200-fold) (Fig. 1c) . Analysis of IFN protein levels by ELISA revealed that IL-29/IL-28B levels were increased 9-fold and that the IFN-β level was undetected in the control group but increased to ~100 pg/ml in the miR-122-transfected group (Fig. 1d) . We also performed the same assays in Huh7 cells.
Although not highly significant, miR-122 increased p-STAT1 ( Supplementary Fig. 1c 
miR-122 enhances the IFN response to mutant HCV or poly(I:C)
Considering that miR-122 can bind to the HCV 5′ UTR and enhance viral replication, the effect of miR-122 on IFN activation might be caused by an increase in HCV RNA abundance. However, the HCV RNA level was only slightly higher (~ 1.5-fold) in miR-122-treated cells than in control-treated cells ( Supplementary Fig. 1e ), suggesting that this assumption is incorrect. We then compared the IFN response to full-genomic (JFH1) and subgenomic HCV (SGR-JFH1) 42 RNA levels and found that the effect of miR-122 on SGR-JFH1-induced IFNs ( Supplementary Fig. 1f ) was similar to the effect on JFH1-induced IFNs (Fig. 1c) , suggesting that miR-122 regulates IFNs independent of infectious virus production. To determine whether the miR-122-induced promotion of IFN activation depends on miR-122 binding to the HCV 5′ UTR, we studied a viral RNA mutant (JFH1-M) with single base substitutions in S1 and S2 (Fig. 1f ) that ablate miR-122 binding 30 . Remarkably, the mutant viral RNA also induced robust IFN synthesis and p-STAT1, which were further enhanced by miR-122 ( Fig. 1 g, h), indicating that binding to HCV RNA is not required for the effect of miR-122 on IFNs.
Furthermore, miR-122 also enhanced the IFN response to poly(I:C), a synthetic analogue of double-stranded RNA (dsRNA) (Fig. 1i , j, Supplementary Fig. 1 g) , indicating that the effect of miR-122 on the IFN response is not specific to HCV but is functional with other viruses.
miR-122 promotes the IFN response by suppressing STAT3 phosphorylation
To understand the mechanism by which miR-122 regulates IFN activation, we performed reporter assays on four immune signalling pathways, including nuclear factor kappa B (NF-κB), interferon regulatory factor 1 (IRF1), type I IFN (using interferon-stimulated response element, ISRE), and STAT3. Consistent with the up-regulation of IFN production and p-STAT1 in the above results, miR-122 up-regulated ISRE promoter activity 24 h after SGR-JFH1 RNA treatment ( Supplementary Fig. 2a ). miR-122 also up-regulated the activity of IRF1, a key transcriptional regulator of the IFN response ( Supplementary Fig. 2a ). In contrast, miR-122 significantly repressed STAT3-and NF-κB-responsive promoters both before and after HCV RNA transfection (Fig. 2a, Supplementary Fig. 2a ).
While of HCV RNA stimulation (Fig. 2b) . Although miR-122 appears to slightly down-regulate STAT3 mRNA expression, this alteration was extremely mild (Supplementary Fig. 2b ).
Comparing the effects of miR-122 overexpression and small interfering RNA (siRNA)-mediated STAT3 knockdown confirmed the specific regulation of miR-122 on phosphorylated STAT3 (Fig. 2c, Supplementary Fig. 2c ). Next, we analysed the IFN response following STAT3 knockdown and HCV RNA stimulation. Excitingly, STAT3 knockdown greatly increased IFN production and p-STAT1 induction (Fig. 2d , e, f). Notably, the IFN level was significantly higher in the STAT3 knockdown cells than in the miR-122-treated cells (Fig. 2d) . The analysis of the effects of STAT3 knockdown on p-STAT1 or IFN activation using JFH1-M or poly(I:C) revealed similar results ( Fig. 2 g, Supplementary Fig.   2d , e). Furthermore, blocking STAT3 phosphorylation by the chemical inhibitor S3I-201 47 or the natural compound cryptotanshinone (CTS) 48 ( Supplementary Fig. 2f ) also significantly increased the IFN response (Fig. 2h, i) . Therefore, these data demonstrate that miR-122
regulates IFN activation via repressing STAT3 phosphorylation.
STAT3 inhibits IRF1 by binding to IRF1 promoters and enhancers
To understand how STAT3 regulates IFN transcriptional activation, we analysed the expression of five transcription factors responsible for IFN activation: IRF1, IRF3, IRF7, RELA and NFKB1 (also known as NF-κB p65 and p50). Both miR-122 overexpression and STAT3 knockdown substantially increased IRF1 expression at 24 h post HCV RNA transfection but did not significantly impact the other expression levels (data on IRF7 is not shown because it could be hardly detected) (Fig. 3a) . Analysis of the protein expression of IRF1 and IRF3 at different times after HCV RNA stimulation showed that STAT3 knockdown increased IRF1 activation very early or even in unstimulated cells (Fig. 3b) , suggesting that IRF1 up-regulation might account for the increased IFN activation. As expected, IRF1
overexpression directly triggered IFN expression ( Fig. 3c ) and STAT1 phosphorylation (Fig.   3d ). Notably, IRF1 overexpression mainly induced IFN-λ expression (Fig. 3d) , which is consistent with a recent report showing that IRF1 is specifically required for IFN-λ activation 49 . Moreover, IRF1 induced STAT1 phosphorylation and MDA5 expression in a dose-dependent manner, and even a small amount of IRF1 significantly increased p-STAT1 and MDA5 expression (Fig. 3e) . Comparing IRF1 activity to that of six known transcriptional regulators of IFN-β 50 also revealed that IRF1 is the major inducer of p-STAT1 (Fig. 3f) . A previous study suggested that STAT3 sequesters STAT1 into STAT1:STAT3 heterodimers and thus inhibits STAT1-dependent IRF1 activation 45 . However, in our system, STAT3
knockdown did not increase the IRF1 induction by either IFN-β or IL-29 (Fig. 3g) , suggesting that STAT3 mainly represses HCV-induced IRF1 activation.
Genome-wide chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project have revealed seven STAT3 binding clusters (BS1 to BS7) on the IRF1 gene locus, and there are three conserved binding motifs for STAT3 within BS1, BS3 and BS4
( Fig. 4a, Supplementary Fig. 3a , b, Supplementary appeared to bind to four sites (BS1, BS2, BS3 and BS4) and weakly bound to the other three sites (Fig. 4b) . Interestingly, using an antibody that specifically recognizes p-STAT3(Tyr705),
we found that p-STAT3 bound to BS2, BS3 and BS4 but not BS1 (Fig. 4b) . By comparison, RELA, an activator of IRF1 (Fig. 3f) , only weakly bound to BS1, BS2 and BS4 (Fig. 4b ).
These data indicate that STAT3 can directly bind several sites on the IRF1 gene.
To determine which sites are critical for IRF1 regulation, we generated a series of luciferase reporter constructs (Fig. 4a) and assessed their activities. Constructs P1 to P6 each harbour a DNA fragment that completely includes the BS1 to BS6 clusters, respectively. Constructs P7 to P11 contain longer DNA inserts that cover one or more ChIP-seq clusters. Consistent with previous studies demonstrating that the IRF1 promoter is located immediately upstream of the IRF1 transcriptional start site (TSS1 in Fig. 4a ) 51 , the activities of the P1 and P7 constructs (both constructs contain the putative promoter sequences) were substantially higher than those of all the other constructs (Fig. 4c) . Although there is another TSS (TSS2) for IRF1, the activities of constructs P8 to P11 were relatively low in HepG2 cells (Fig. 4c) , suggesting that this alternative TSS may be minimally utilized in HepG2 cells. Notably, the activities of constructs P1, P7, P4, P10 and P11 were significantly increased by poly(I:C) transfection, whereas the others were not (Fig. 4c) , indicating that activating elements are located within P1 (BS1) and P4 (BS4).
To assess the effect of STAT3 on P1, P7 and P4, constructs were co-transfected into 293FT cells with a STAT3-expressing plasmid. As expected, STAT3 inhibited the activities of all three constructs ( 5c ). In addition, we found that gp130 is downstream of STAT3
( Supplementary Fig. 5d ). Thus, miR-122 may regulate some undefined regulators of p-STAT3.
To search for the genes that mediate miR-122 regulation of p-STAT3, we first performed microarrays to obtain the genes repressed by miR-122 and then screened for STAT3 activators ( Table 2 ). According to several references, we collected a total of 330 known and potential STAT3 activators that were detected in our microarray (Supplementary Table 3 ). Among the 330 candidates, 25 genes were down-regulated by miR-122 (Supplementary Table 4 ). The qRT-PCR data confirmed that 20 genes were significantly down-regulated by miR-122 ( Fig. 5b ), but the remaining five genes were hardly detected or were unchanged (data not shown).
To determine whether these genes mediated the effect of miR-122 on p-STAT3 and the IFN response, we first performed knockdown experiments ( Supplementary Fig. 7 ). While knocking down most genes (except for FGFR1, DSTYK, ABL2 and OSMR) reduced the p-STAT3 level, the knockdown of ten genes (MERTK, EPO, FGFR1, JAK3, PKM2, IGF2, IL8, ABL2, MAK3K3 and FGF11) appeared to increase the p-STAT1 level (Fig. 5c) . Notably, some of these genes (MERTK, EPO, JAK3, PKM2 and IL8) significantly affected both p-STAT1 and p-STAT3. The qRT-PCR data confirmed that p-STAT1 up-regulation was accompanied by an increase in IFN expression (Fig. 5d ). Next, we performed overexpression experiments on ten genes, which were selected for because their knockdown either significantly increased p-STAT1 levels (FGFR1, IGF2, ABL2 and FGF11), significantly reduced p-STAT3 levels (IL1RN and IGF1R), or both (MERTK, EPO, JAK3 and PKM2).
JAK1 and EGFR, two well-characterized STAT3 activators, were employed as positive controls. Most likely, because STAT3 was constitutively phosphorylated in HepG2 cells, the overexpression of most of these genes did not further increase the p-STAT3 level in HepG2 cells (Fig. 5e ). However, in Huh7 or 293FT cells, the overexpression of most of the genes increased p-STAT3 levels ( Fig. 5f, g ). In particular, FGFR1, IGF1R, MERTK, JAK3 and FGF11 clearly up-regulated p-STAT3 levels, but the effect was slightly different in the two cell lines (Fig. 5f, g ). Taken together, these results demonstrate that miR-122 may regulate STAT3 phosphorylation and the IFN response through repressing several STAT3 activators.
miR-122 targets receptor tyrosine kinase (RTK) signalling
To further understand how miR-122 regulates p-STAT3 levels, we assessed the expression of all 20 genes in HepG2 and Huh7 cells and in a normal human liver sample. Interestingly, the mRNA expression of six genes (IGF1R, PKM2, FGFR1, FGF11, IGF2 and MERTK) was significantly higher (>2-fold) in the HepG2 cells than in the normal liver cells (Fig. 6a ),
suggesting that these genes might account for the persistent STAT3 activation in HepG2 cells.
To determine which gene was most influential, we again performed knockdown experiments with a higher dose of siRNAs (50 nM). Remarkably, while PKM2 and IGF2 knockdown moderately decreased p-STAT3 levels, MERTK and IGF1R knockdown markedly decreased the p-STAT3 level (Fig. 6b) Fig. 8 ). To investigate if miR-122 directly regulates these genes, we generated reporter constructs as previously described 56 and performed Fig. 9 ). These results may explain why STAT1 is phosphorylated in HepG2 cells without HCV RNA treatment and why miR-122 initially inhibited p-STAT1 (Fig. 1b) . Intriguingly, when we transfected poly(I:C) into PC3 cells, a prostate cancer cell line that lacks STAT3 in the genome 62 , we found that the IFN activation was faster and stronger than that in HepG2 cells ( Supplementary Fig. 10a ). Moreover, plasmid DNA transfection into PC3 cells also resulted in high IFN production ( Supplementary Fig. 10b ). In summary, we 
DISCUSSION

MATERIALS AND METHODS
Mimics
Cell lines
Huh7.5.1 was described 40 . HepG2 and Huh7 cell lines were obtained from Cell Bank of Chinese Academy of Sciences (Shanghai). 293FT cell line was obtained from Invitrogen.
miR-122-Tet-On HepG2 cell line was generated using lentiviral vectors. Briefly, the transfer vector for expression of miR-122 hairpins ( Supplementary Fig.6a ) was generated by insertion of the TRE-3G promoter (P TRE3G, from pTRE3G-IRES, Clonetech), GFP-miR-122x4 cassette 56 , PGK promoter (P PGK ) and Neomycin resistance gene into the transfer vector of a third-generation lentiviral vector system. The transfer vector for expression of Tet3G
( Supplementary Fig.6a ) was generated by insertion of EF1α promoter (P EF1A ), Tet3G (from pCMV-Tet3G, Clonetech), internal ribosome entry site (IRES) and Blasticidin resistance gene into another transfer vector. Lentiviruses were generated in 293FT cells according to the manual of ViraPower Lentiviral Packaging Mix (Invitrogen, K4975-00). HepG2 cells were infected with lentiviruses one after another, selected with G418 (1000 μg/ml) and Blasticidin (10 μg/ml) until cells do not die any more.
Viral constructs and viral RNA preparation
pJFH1 and pSGR-JFH1 were described 42 . pJFH1-M was generated by the introduction of two point mutations (A-T) in the miR-122 binding sites on pJFH1. Viral RNAs were prepared by in vitro transcription (Ambion, AM1333). HCV RNAs were prepared as described 40 .
Constructs
STAT3, NF-κB, IRF1 and ISRE reporter vectors were included in Cignal Finder™
Multi-Pathway Reporter Array (SABiosciences, CCA-901L). Eleven IRF1 promoter or enhance constructs were generated based on pGL3-basic (Promega). Mutations were introduced by PCR. Detailed information on the position of DNA fragment can be found in Supplementary Table 1 . Reporter vectors for miR-122 binding sites were generated as described 56 . HA-IL1RN, HA-EPO, IGF2-HA and HA-FGF11). pcDNA3-RFP and pRKW2-HA-GFP were used as controls. All oligonucleotides used in this work can be found in Supplementary Table   5 .
Analysis of STAT3 binding sites on IRF1
ChIP-seq binding sites for STAT3 was analyzed on UCSC genome browser (GRCh37/hg19) using the "ENCODE Regulation Super-track", and Txn Factor ChIP data (161 Transcription Factor) was selected. Seven STAT3 binding clusters within IRF1 locus ( Supplementary Fig. 3a) were obtained and selected for ChIP-PCR assays (Supplementary Table 1 
Collection of Candidate STAT3 Activators
We totally collected 330 candidates (known and potential) that can be detected in our microarray data (Supplementary Table 3) , by strategies as follows:
(1) In the website of R&D systems (5) We also collected potential RTKs, ligands, as well as RTK-related genes based on their names.
Cell cultures and transfections
HepG2 and miR-122-Tet-On HepG2 cells were maintained in MEM supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin).
PC3 was maintained in F-12K (Sigma, N3520) supplemented with 10% FBS and antibiotics.
Huh7-derived cell lines were maintained in DMEM supplemented with 10% FBS and antibiotics.
Mimics and siRNAs were reversely transfected into cells using Lipofectamine 
qRT-PCR
28
Total RNA was isolated with Trizol reagent (Invitrogen). The expression of mRNAs, HCV RNA and miR-122 were quantified by SYBR Green-based Real-time PCR. Reverse transcription (RT) reactions for mRNAs were done using GoScript™ RT System (Promega, A5000), with random primers and oligo dT. RT reactions for miR-122 were done using PrimeScript™ RT reagent Kit with gDNA Eraser (TaKaRa, 047A), with a stem-loop primer.
RT reactions for HCV RNA were performed using SuperScript ® III Reverse Transcriptase, with a specific primer. qPCRs were performed with GoTaq® qPCR Master Mix (Promega, A6002).
Western blots
Total protein of cell lines and liver tissues were prepared using RIPA buffer (50mM Tris-HCl, 
Statistical Analysis
Data are representative of at least three independent experiments. For statistical analysis, the differences were analyzed using two-sided Student's t-tests when comparing the effect of two factors on the same subjects, or one-way analysis of variance (ANOVA) when comparing the effect of multiple factors. A P value < 0.05 was considered statistically significant. *P < 0.05, **P < 0.01 and ***P < 0.001. Error bars represented standard error of the mean (SEM) in
qRT-PCR and ELISA data, or standard deviation (SD) in luciferase data. shown as the mean ±SEM. *P < 0.05, **P < 0.01 and ***P < 0.001. as the mean ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001. 
